ERBITAG: Non-interventional study on the efficacy of cetuximab in first-line therapy in patients with RAS wild-type metastatic colorectal cancer

Abstract Background Metastatic colorectal cancer (mCRC) is a difficult-to-treat disease with poor clinical outcomes. Systemic chemotherapy in combination with targeted anti-EGFR therapy has expanded the treatment options for mCRC. However, the therapeutic efficacy of anti-EGFR regimens and relevant...

Descrición completa

Detalles Bibliográficos

Principais autores:	Stephan W. Sahm, Ulf Peter Neumann, Mark-Oliver Zahn, Michael Schwittay, Christoph Maintz, Thomas Goehler, Oleg Rubanov, Christiane Hering-Schubert, Jan Janssen, Karsten Stenzel, Julia Reinke, Friedrich Overkamp
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMC 2026-02-01
Series:	BMC Cancer
Assuntos:	Cetuximab Cetuximab-based combinational chemotherapy Colorectal cancer Metastatic colorectal cancer Non-interventional study First-line therapy
Acceso en liña:	https://doi.org/10.1186/s12885-026-15753-5
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!